Summary of Key Points Core Viewpoint - The financing balance of the Sci-Tech Innovation Board (STAR Market) has increased, indicating a growing interest in investments within this sector, with notable changes in both financing and securities lending balances [1][2]. Financing Balance - As of May 21, the total financing balance on the STAR Market reached 1527.37 billion yuan, an increase of 2.87 billion yuan from the previous trading day, marking three consecutive days of growth [1]. - The highest financing balance is held by SMIC (中芯国际) at 75.19 billion yuan, followed by Cambrian (寒武纪) and Haiguang Information (海光信息) with balances of 48.34 billion yuan and 32.99 billion yuan, respectively [1]. - A total of 343 stocks saw an increase in financing balance, while 240 stocks experienced a decrease. The stocks with the largest increases in financing balance were Jingwei Hengrun (经纬恒润), Kexing Pharmaceutical (科兴制药), and Guangge Technology (光格科技), with increases of 20.46%, 20.08%, and 19.38% respectively [1][2]. Securities Lending Balance - The total securities lending balance on the STAR Market reached 5.47 billion yuan, with an increase of 891.53 million yuan from the previous trading day [1]. - The highest securities lending balance is held by Haiguang Information at 0.20 billion yuan, followed by SMIC and Cambrian, both at 0.18 billion yuan [2]. - A total of 123 stocks saw an increase in securities lending balance, while 137 stocks experienced a decrease. The stocks with the largest increases in securities lending balance were Ruikeda (瑞可达), Maixinlin (迈信林), and Xidiwei (希荻微), with increases of 313.91%, 273.38%, and 224.07% respectively [2].

Group 1 - The core point of the news is that the company Sanofi Guojian has signed a licensing agreement with Pfizer for the exclusive development, production, and commercialization of the 707 project, which targets both PD-1 and VEGF [1] - Pfizer will pay an upfront fee of $1.25 billion, which sets a new record for upfront payments for domestic innovative drugs going abroad, and the total potential payments could reach up to $4.8 billion [1] - The agreement signifies recognition of the R&D capabilities of domestic innovative drug companies by top international pharmaceutical firms, marking a milestone for domestic pharmaceutical companies in entering the global market [1] Group 2 - The 707 project is a bispecific antibody product that requires internal decision-making processes and regulatory approvals before implementation, indicating some uncertainty in the execution [1] - The domestic pharmaceutical industry has seen significant growth in recent years, supported by domestic pharmaceutical policies and capital market financing policies for innovative drug R&D [1] - Over 25 domestic Class 1 innovative drugs have been approved for listing on the Sci-Tech Innovation Board, and more than 10 innovative drug companies have granted overseas rights to foreign companies through licensing agreements [2]

Group 1 - Kingoo Co., Ltd. received a 10-year long-term order from a global leading automotive company to develop wheel products for American passenger cars, with expected sales of approximately $158 million over the first five years [1] - Shanghai Xiba plans to acquire several patents from the Chinese Academy of Sciences for a total of 2.5 million yuan and establish two subsidiaries to promote technology commercialization [2] - Sichuan Gold announced that two major shareholders plan to reduce their stakes by 2.5% and 3% respectively, citing personal funding needs [3] Group 2 - Yitian Co. intends to acquire 40% of its subsidiary Yitian Semiconductor for 1 yuan, increasing its ownership to 100% [6] - Xiyu Tourism's major shareholder plans to reduce its stake by up to 3% within three months due to operational needs [7] - Longqi Technology is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance capital strength and international competitiveness [9] Group 3 - Kexing Pharmaceutical received FDA approval for clinical trials of its innovative drug GB18 injection in the U.S., targeting cancer cachexia [19] - Lisheng Pharmaceutical's subsidiary will receive a cash dividend of 304 million yuan from its investment in Tian Shili Biological [21] - Shanghai Laishi's controlling shareholder plans to increase its stake in the company by 250 million to 500 million yuan to boost investor confidence [22]

证券代码：688136 证券简称：科兴制药 公告编号：2025-027 科兴生物制药股份有限公司 自愿披露关于创新药 GB18 注射液 获得美国 FDA 新药临床试验许可的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，科兴生物制药股份有限公司（以下简称"公司"）全资子公司深圳科兴 药业有限公司（以下简称"深圳科兴"）收到美国食品药品监督管理局（以下简称 "FDA"）的通知，深圳科兴自主研发的创新药GB18注射液药品临床试验申请已 获得FDA批准，可在美国开展临床试验，适应症为治疗肿瘤恶病质。现将相关情 况公告如下： 1 一、许可基本情况 药品名称：GB18注射液 申请事项：美国境内开展临床试验 申请编号：IND 175450 审评结论：本药品临床试验申请获得美国FDA批准，同意本药品按照提交的 方案开展临床研究。 二、GB18注射液基本情况 GB18注射液是一种针对GDF15（生长分化因子15）靶点的创新型药物，用 于治疗肿瘤恶病质。该分子采用了独特的Fc融合纳米抗体结构设计，不仅提高了 药物的稳定性和生物利 ...

5月20日，A股市场整体上涨。 截至收盘，上证指数收报3380.48点，上涨0.38%；深证成指收报10249.17点，上涨0.77%；创业板指 收报2048.46点，上涨0.77%。两市合计成交11696.81亿元，较上一交易日增加832.34亿元。 1. 两市主力资金净流出近20亿元 3.传媒等行业实现净流入 | | | 资金净流入居前的行业 | | | --- | --- | --- | --- | | 行业 | 涨跌幅 | 净流入资金 (亿元) | 资金流入较多个股 | | 传媒 | 1.93% | 39.80 | 汤姆猫 | | 医药生物 | 1.88% | 37.70 | 药明康德 | | 公用事业 | 1. 29% | 27. 53 | 国电电力 | | 食品饮料 | 1. 75% | 16. 06 | 伊利股份 | | 农林牧渔 | 2. 37% | 14. 44 | 回盛生物 | | 行业 | 涨跌幅 | 净流入资金 (亿元) | 资金流出较多个股 | | --- | --- | --- | --- | | 基础化工 | 0. 57% | -43. 37 | 红宝丽 | | 机械设备 | 1 ...

Core Viewpoint - The animal vaccine sector has shown a significant increase, with a 4.00% rise, ranking third among concept sectors, driven by notable gains in several stocks [1][2]. Group 1: Sector Performance - As of May 20, the animal vaccine concept increased by 4.00%, with 19 stocks rising, including *ST Xianfeng, which hit the daily limit, and others like Kexing Pharmaceutical, Ruipu Biological, and Kanghua Biological, which rose by 15.56%, 8.41%, and 6.70% respectively [1][2]. - The animal vaccine sector was among the top-performing sectors, alongside cultivated diamonds and pet economy, which rose by 4.10% and 4.08% respectively [2]. Group 2: Capital Inflow - The animal vaccine sector saw a net inflow of 67 million yuan, with 13 stocks receiving net inflows, and 6 stocks attracting over 10 million yuan in net inflows [2]. - Jinhe Biological led the net inflow with 36.88 million yuan, followed by Kexing Pharmaceutical, Dabeinong, and Plk, which received net inflows of 15.38 million yuan, 13.79 million yuan, and 13.60 million yuan respectively [2][3]. Group 3: Capital Flow Ratios - Stocks such as *ST Xianfeng, Kexing Pharmaceutical, and KQ Biotech had the highest net inflow ratios, at 14.17%, 6.56%, and 5.52% respectively [3]. - The top stocks in terms of capital inflow included Jinhe Biological with a turnover rate of 18.22% and a daily increase of 4.40%, and Kexing Pharmaceutical with a turnover rate of 3.46% and a daily increase of 15.56% [3][4].

转自：新华财经 新华财经北京5月20日电（罗浩）科创50指数5月20日早间小幅高开，指数盘初回踩缺口后快速反弹，涨 近0.5%后有所回落，此后震荡上扬，午后涨幅收窄，收盘时小幅上涨。至收盘时，科创50指数报997.68 点，涨幅0.24%，指数振幅为0.83%，总成交额约175.15亿元。 20日，科创综指小幅高开，指数盘初震荡上扬，午后窄幅整理，收盘时涨0.53%，收于1178.22点，总成 交额约729亿元，成交额微幅放量。 科创板整体行情延续活跃态势，5月20日创下阶段新高的科创板股票继续增多。经新华财经统计，5月20 日创下2025年以来新高、30个交易日新高、20个交易日新高的科创板股票家数分别为32只、76只，109 只，上一交易日相关数据分别为24只、48只、59只。 细分领域方面，20日生物制药股涨幅靠前，三生国健、荣昌生物、益方生物、科兴制药分别上涨 19.99%、16.09%、15.62%、15.56%，居当日科创板涨幅前四位。20日，科创板中的部分医疗保健股、 家用电器股、矿物制品股亦有较大幅度上涨。 经新华财经统计，5月20日，科创板587只个股平均涨幅0.98%，平均换手率2.16% ...

Industry Overview - The recombinant protein sector has shown active performance, with a nearly 4% increase in the market as of May 20, highlighted by stocks such as Yipinhong (300723) and Weiming Pharmaceutical (002581) reaching their daily limit [1] - Recombinant proteins are produced using recombinant DNA or RNA technology, allowing host cells to express proteins that are either identical to or modified versions of natural proteins, enhancing properties like solubility or yield [1] - Key applications of recombinant proteins include biopharmaceuticals, cell immunotherapy, and diagnostic reagent development, playing a crucial role in vaccine production, monoclonal antibodies, and innovative drugs for cancer treatment, autoimmune diseases, and rare diseases [1] Market Growth - The global recombinant protein market grew from $7 billion in 2015 to $10.8 billion in 2020, with a compound annual growth rate (CAGR) of 9.0%, and is projected to reach $20.8 billion by 2025, with a CAGR of approximately 14.1% from 2020 to 2025 [2] - Historically, the global recombinant protein market has been dominated by international brands, but domestic companies are increasingly investing in R&D to enhance their technology and product quality, leading to a significant trend of import substitution [2] Company Highlights - Yipinhong has established a recombinant protein R&D and pilot production facility, enabling capabilities in biopharmaceutical development [3] - Weiming Pharmaceutical's subsidiary, Shandong Yandu, has developed a high-expression recombinant protein platform, creating multiple biopharmaceutical R&D systems [3] - Sangfor Biopharma focuses on innovative therapeutic antibody drugs, specializing in monoclonal antibodies, bispecific antibodies, and multifunctional recombinant proteins [3] - Kexing Pharmaceutical is a leading company in China's recombinant protein drug sector, with a comprehensive biopharmaceutical R&D innovation system [4] - Furuida has been deeply involved in the recombinant collagen field, utilizing synthetic biology techniques to select high-bioactive segments from human type III collagen [4] - Saiseng Pharmaceutical has formed a technical system centered on proteomics, antibody platforms, drug R&D, and fine recombinant protein production [4] - Jieya Co., Ltd. has partnered with Chuangjian Medical to establish Anhui Jiechuang Medical Equipment Co., Ltd., focusing on recombinant collagen protein business [4] - Shenzhou Cell has developed a high-efficiency, high-throughput technology platform covering the entire biopharmaceutical R&D and production chain, with a diverse pipeline of monoclonal antibodies, recombinant proteins, and vaccines [4]

Group 1 - The core viewpoint indicates that the domestic innovation opportunities outweigh challenges, with a potential shift towards "source innovation" and integration into the global industrial chain restructuring [3] - The ChiNext Composite Index ETF (Hua Xia) closely tracks the performance of the ChiNext Composite Index, reflecting the overall performance of eligible companies listed on the ChiNext board, including dividend income [4] - Recent performance shows that the ChiNext Composite Index ETF has seen a 1.19% increase over the past month, with a trading volume of 1.07 billion yuan and a turnover rate of 3.9% [3] Group 2 - The Chinese innovative drug sector is characterized by low R&D costs and high efficiency, positioning it as a preferred choice for business development transactions, with China expected to become a low-cost R&D and production center [4] - The CXO industry chain in China is likely to strengthen its market position as multinational pharmaceutical companies seek to reduce R&D and production costs under stricter pricing systems [4] - There are investment opportunities in segments such as innovative drugs, medical devices, traditional Chinese medicine, medical services, and chain pharmacies [4]

Group 1 - The pharmaceutical sector is experiencing significant activity, with notable stocks such as Sanofi and Yipinhong reaching their daily limit up of 19.99%, and others like Shutaishen rising over 9% [1] - Major pharmaceutical companies reported impressive Q1 earnings, with BeiGene achieving a revenue of 8.048 billion yuan, a 50.2% increase from the previous year, and a significant reduction in net losses [1] - Innovent Biologics reported a revenue of 381 million yuan for Q1, marking a 129.92% year-on-year growth, and a net profit of 18 million yuan, up 112.62% year-on-year, indicating a turnaround to profitability [1] Group 2 - Wanlian Securities forecasts a performance divergence in the pharmaceutical sub-sectors for Q1 2024 and 2025, with strong revenue and profit growth expected in medical R&D outsourcing, hospitals, and other biological products [2] - The chemical pharmaceutical sector is gaining market attention, focusing on innovation-driven growth, domestic production, and policy immunity [2] - China Galaxy notes that the pharmaceutical sector has undergone a long adjustment period, resulting in low valuations and underweight public holdings, with expectations for policy support and market demand recovery to drive growth [2]